Xcout Intel
SenzaGen
SenzaGen provides in vitro skin sensitization testing services and non-animal toxicity testing solutions using its proprietary GARD technology, which combines genomics and machine learning. The company serves industries such as cosmetics, chemicals, and medical devices by offering regulatory-compliant safety testing and advisory services to predict skin sensitization potency without animal testing.
Subscribe to see SenzaGen’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
SenzaGen at a glance
SenzaGen is a biotech, toxicology company headquartered in Sweden. Xcout tracks 5 named people at SenzaGen, including Carl Borrebaeck (Chairman).
SenzaGen leadership
- Carl BorrebaeckChairman
- Anki Malmborg HagerMember of the Board
- Ian KimberMember of the Board
- Paul YianniMember of the Board
- Paula ZeilonMember of the Board
SenzaGen competitors
A few of SenzaGen's closest competitors — see the full list of competitors and alternatives →
Source BioScience is a UK-based laboratory services company providing genomics, DNA sequencing, molecular diagnostics, and pathology-related testing. It serves pharmaceutical and biotechnology companies, healthcare organizations, research institutions, and other life-science customers.
GenDx specializes in molecular diagnostics for transplantation and personalized healthcare, providing pre- and post-transplant reagents, NGS-based typing assays, and analysis software. The company serves diagnostic laboratories, transplant centers, and researchers by offering products and technical support for HLA typing, chimerism monitoring, and related applications.
Olink Proteomics provides high-throughput protein biomarker analysis products, instruments, software, and analysis services for life science research and drug development. Utilizing its proprietary Proximity Extension Assay (PEA) technology and next-generation sequencing, the company serves researchers and pharmaceutical organizations focused on biomarker discovery and precision medicine.
Centogene provides precision medicine solutions through advanced diagnostics, multiomic testing, and bioinformatics platforms. The company serves physicians, patients, and pharmaceutical partners by offering genomic sequencing, biomarker testing, and data-driven insights to accelerate rare disease diagnosis, drug discovery, and personalized therapies.
InsituGen is a biotechnology company founded in 2020 and headquartered in Dunedin, New Zealand. The company develops cellular bioassay technologies to detect androgenic and estrogenic bioactivity.
CellCarta operates as a global contract research organization (CRO) providing specialized laboratory testing and biomarker services to support drug development and precision medicine. The company offers a wide range of services including immunology, proteomics, genomics, histopathology, and companion diagnostic development for pharmaceutical and biotechnology clients.
Get SenzaGen's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on SenzaGen in Xcout Intel
- 5 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access